Literature DB >> 6139183

Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine.

J D Horowitz, E M Antman, B H Lorell, W H Barry, T W Smith.   

Abstract

The biochemical basis of the mechanism of vasodilatation by nitroglycerin (NTG) has not been previously investigated in man. However, evidence from in vitro studies suggests that NTG induces activation of guanylate cyclase via a series of enzymatic reactions that are modulated by the availability of sulfhydryl groups. Cysteine appears to be particularly effective in potentiating guanylate cyclase activation by NTG. To determine whether hemodynamic responsiveness to NTG in man might be modulated by sulfhydryl availability, concentration-response curves for effects of intravenously infused NTG on mean arterial pressure (MAP) and mean pulmonary capillary wedge pressure (PCW) were obtained in 10 patients undergoing cardiac catheterization for investigation of chest pain. NTG infusion was repeated 10 min after the intravenous infusion of 100 mg/kg of the cysteine source N-acetylcysteine (NAC). NAC induced no significant hemodynamic effect, but after NAC infusion there was a significant reduction both in the NTG infusion rate associated with a 10% fall from control values in MAP (25.8 +/- 8.3 to 9.3 +/- 2.7 micrograms/min; p less than .01) and in the infusion rate inducing a 30% reduction in PCW (13.6 +/- 4.6 to 4.2 +/- 1.6 micrograms/min; p less than .02). In a control group of five patients who received no NAC, there was no significant change in responsiveness to NTG between infusions. It is concluded that NAC potentiates the vasodilator effects of NTG in man. This suggests that sulfhydryl availability and/or redox state may be determinants of in vivo responsiveness to NTG.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6139183     DOI: 10.1161/01.cir.68.6.1247

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  23 in total

Review 1.  An update on nitrate tolerance: can it be avoided?

Authors:  S R Maxwell; M J Kendall
Journal:  Postgrad Med J       Date:  1992-11       Impact factor: 2.401

Review 2.  Mechanisms of nitrate tolerance: a review.

Authors:  R J Katz
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 3.  Update on nitrate tolerance.

Authors:  J O Parker
Journal:  Br J Clin Pharmacol       Date:  1992       Impact factor: 4.335

4.  Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance.

Authors:  Andrew S Holmes; Yuliy Y Chirkov; Scott R Willoughby; Susan Poropat; Jeremy Pereira; John D Horowitz
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

Review 5.  Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.

Authors:  S Silber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin.

Authors:  J Loscalzo
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

Review 7.  Intravenous glyceryl trinitrate (nitroglycerin). A review of its pharmacological properties and therapeutic efficacy.

Authors:  E M Sorkin; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1984-01       Impact factor: 9.546

Review 8.  Nitrate tolerance. A review of the evidence.

Authors:  J T Flaherty
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

Review 9.  Pharmacology of endothelium-derived nitric oxide and nitrovasodilators.

Authors:  L J Ignarro; G Ross; J Tillisch
Journal:  West J Med       Date:  1991-01

10.  Paracetamol cardiotoxicity.

Authors:  A Armour; S D Slater
Journal:  Postgrad Med J       Date:  1993-01       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.